Nantong Guangyuan Chemical: difference between revisions
Diff·revision 24 → 25·15:35, 4 Aug 2025
Difference between revision 24 and revision 25 of Nantong Guangyuan Chemical. 4 lines changed; the page grew by 860 bytes.
| Revision 24 — 08:35, 14 Jul 2025 GroupBuyGalen (talk) attribute the capability claim to the organisation's own material 13,335 bytes +207 | Revision 25 — 15:35, 4 Aug 2025 StubSorterBot (talk) bot: mark outbound storefront link nofollow 14,195 bytes +860 | ||
|---|---|---|---|
| 96 | What is '''not''' available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.{{r|selfpub}} | 96 | What is '''not''' available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.{{r|selfpub}} |
| 97 | 97 | ||
| + | 98 | Two frameworks are named in this article only to say what has ''not'' been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,{{r|gmp}} and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.{{r|iso17025}} Neither assessment is available here for this organisation or for any other covered on this wiki. | |
| + | 99 | ||
| 98 | == References == | 100 | == References == |
| 99 | {{reflist}} | 101 | {{reflist}} |
| ⋮ | ⋮ | ||
| 103 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 105 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| 104 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 106 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| + | 107 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''. International Organization for Standardization.</ref> | |
| 105 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 108 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| + | 109 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | |
| 106 | 110 | ||
| 107 | == Further reading == | 111 | == Further reading == |